On January 21, 2025 Breakpoint Therapeutics GmbH ("Breakpoint"), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), reported that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in an oral presentation at the DDR Inhibitors Summit, being held January 27-29, 2026 in Boston (MA), USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DNA polymerase theta is a DNA repair enzyme that is largely absent in normal cells but displays aberrant expression in multiple cancer types which often correlates with poor prognosis. Inhibition of Pol θ is a validated therapeutic modality in certain tumour-specific contexts.

Details of the presentation are as follows:

Title: Targeting Polθ’s Dual Domains to Guide Candidate Selection & Strategic Partnering

Date: Wednesday, 28 January, 2026

Time: 11:00 – 11:30 a.m. ET

In addition, Jon will participate in a panel discussion on the topic of "Uniting Founders and Funders to Align Scientific Vision with Investment Strategy" scheduled for Thursday, 29 January, 2026 at 8:30am.

(Press release, Breakpoint Therapeutics, JAN 21, 2026, View Source [SID1234662127])